Zydus Lifesciences: Reports Good Results From Its Evidence-X Phase II(B) Clinical Trial For Saroglitazar MG In MASH; The Trial Met Its Main Goal Of Resolving Steatohepatitis Without Increasing Fibrosis.

 31 Aug 2026 10:44 AM

Zydus Lifesciences: Reports Good Results From Its Evidence-X Phase II(B) Clinical Trial For Saroglitazar MG In MASH; The Trial Met Its Main Goal Of Resolving Steatohepatitis Without Increasing Fibrosis.

Zydus Life: Macquarie on Zydus Life Maintains Outperform with Target Price of ₹1,285 as strategic mix shift is expected to lift EBITDA margins to 27–28%, Saroglitazar and a robust US generics pipeline strengthen growth visibility, while domestic business is expected to outgrow IPM by 300–500bps and international formulations and consumer wellness remain growth drivers.

 27 Aug 2026 08:55 AM

Zydus Life: Macquarie on Zydus Life Maintains Outperform with Target Price of ₹1,285 as strategic mix shift is expected to lift EBITDA margins to 27–28%, Saroglitazar and a robust US generics pipeline strengthen growth visibility, while domestic business is expected to outgrow IPM by 300–500bps and international formulations and consumer wellness remain growth drivers.

Zydus Lifesciences: Co. Incorporates Unit Named Zydus Global Treasury Centre Ifsc Limited In Gift City, Gandhinagar.

 26 Aug 2026 11:13 AM

Zydus Lifesciences: Co. Incorporates Unit Named Zydus Global Treasury Centre Ifsc Limited In Gift City, Gandhinagar.

Zydus Lifesciences: Company Gets Final USFDA Approval For Ascorbic Acid Injection With 180-Day CGT Exclusivity; Product To Treat Scurvy, Made In USFDA-Approved Plant In Gujarat.

 21 Aug 2026 01:54 PM

Zydus Lifesciences: Company Gets Final USFDA Approval For Ascorbic Acid Injection With 180-Day CGT Exclusivity; Product To Treat Scurvy, Made In USFDA-Approved Plant In Gujarat.

HC bars Zydus Life from launching drug with Novartis-patent Dabrafenib

 18 Aug 2026 11:28 AM

HC bars Zydus Life from launching drug with Novartis-patent Dabrafenib

Zydus: Jefferies on Zydus Maintains Buy with Target Price of ₹1,370 as 1QFY27 growth remained strong across India and international markets, US sales rose 5% QoQ on new launches, FY27 guidance was retained, and FTF launches and innovative products support growth beyond FY27 despite a 3% FY27 EPS cut.

 12 Aug 2026 09:04 AM

Zydus: Jefferies on Zydus Maintains Buy with Target Price of ₹1,370 as 1QFY27 growth remained strong across India and international markets, US sales rose 5% QoQ on new launches, FY27 guidance was retained, and FTF launches and innovative products support growth beyond FY27 despite a 3% FY27 EPS cut.

Zydus: HSBC on Zydus Maintains Hold with Target Price of ₹1,100 as 1Q revenue growth was healthy but EBITDA margins missed estimates due to higher costs, while FY27 guidance was retained and branded-product initiatives are expected to build gradually, with saroglitazar magnesium FDA approval the next key catalyst.

 12 Aug 2026 09:04 AM

Zydus: HSBC on Zydus Maintains Hold with Target Price of ₹1,100 as 1Q revenue growth was healthy but EBITDA margins missed estimates due to higher costs, while FY27 guidance was retained and branded-product initiatives are expected to build gradually, with saroglitazar magnesium FDA approval the next key catalyst.

Zydus: CLSA on Zydus Maintains Outperform with Target Price of ₹1,310 as 1QFY27 growth was healthy across ex-US segments, margins remained in line despite higher acquisition-related opex, FY27 double-digit revenue growth and 24% margin guidance were retained, and Assertio consolidation plus upcoming US launches support higher FY27–29 estimates.

 12 Aug 2026 09:04 AM

Zydus: CLSA on Zydus Maintains Outperform with Target Price of ₹1,310 as 1QFY27 growth was healthy across ex-US segments, margins remained in line despite higher acquisition-related opex, FY27 double-digit revenue growth and 24% margin guidance were retained, and Assertio consolidation plus upcoming US launches support higher FY27–29 estimates.

Zydus: Citi on Zydus Maintains Sell with Target Price of ₹1,040 as EBITDA of ₹18.7bn beat estimates by 5% on strong 19.5% YoY India growth and resilient Mirabegron sales, while consolidated revenue grew 22% YoY with 12% from acquisitions and FY27 double-digit growth and ~24% EBITDA margin guidance were reiterated.

 12 Aug 2026 09:04 AM

Zydus: Citi on Zydus Maintains Sell with Target Price of ₹1,040 as EBITDA of ₹18.7bn beat estimates by 5% on strong 19.5% YoY India growth and resilient Mirabegron sales, while consolidated revenue grew 22% YoY with 12% from acquisitions and FY27 double-digit growth and ~24% EBITDA margin guidance were reiterated.

Zydus Life: Assertio Holdings Projected to Add $15 Million to $20 Million Quarterly Starting Next Quarter. The Consumer Wellness Sector Expected to See Strong Double-Digit Growth for FY '27. Over Five Years, Branded Business Aims for EBITDA Margins of 28%-30% Plus.

 12 Aug 2026 08:44 AM

Zydus Life: Assertio Holdings Projected to Add $15 Million to $20 Million Quarterly Starting Next Quarter. The Consumer Wellness Sector Expected to See Strong Double-Digit Growth for FY '27. Over Five Years, Branded Business Aims for EBITDA Margins of 28%-30% Plus.

Zydus Life: Keeps EBITDA Margin Target At Over 24% For FY '27 Despite Expected Higher Expenses For Saroglitazar In The Second Half Of The Year. Saroglitazar Is Set To Launch In FY '28 In The U.S., With Initial Years Focused On Investment And Expected Peak Sales Of $200M To $300M, Possibly Surpassing $400M.

 12 Aug 2026 08:39 AM

Zydus Life: Keeps EBITDA Margin Target At Over 24% For FY '27 Despite Expected Higher Expenses For Saroglitazar In The Second Half Of The Year. Saroglitazar Is Set To Launch In FY '28 In The U.S., With Initial Years Focused On Investment And Expected Peak Sales Of $200M To $300M, Possibly Surpassing $400M.

Zydus Life: Company Expects Strong Double-Digit Revenue Growth For FY '27, With India Division Projected To Grow In The Mid-Teens, Surpassing Market By 3% To 5%. U.S. Business Anticipates Single-Digit Growth.

 12 Aug 2026 08:39 AM

Zydus Life: Company Expects Strong Double-Digit Revenue Growth For FY '27, With India Division Projected To Grow In The Mid-Teens, Surpassing Market By 3% To 5%. U.S. Business Anticipates Single-Digit Growth.

Zydus Life: Expects Over Two-Thirds Of Revenue From Branded Portfolio, U.S. Business To Grow From 10% To 15% By Fiscal Year End

 12 Aug 2026 08:43 AM

Zydus Life: Expects Over Two-Thirds Of Revenue From Branded Portfolio, U.S. Business To Grow From 10% To 15% By Fiscal Year End

ZYDUS LIFESCIENCES: Q1 CONS NET PROFIT 9.4B RUPEES VS 14.7B (YOY); EST 10B

 11 Aug 2026 01:23 PM

ZYDUS LIFESCIENCES: Q1 CONS NET PROFIT 9.4B RUPEES VS 14.7B (YOY); EST 10B

ZYDUS LIFESCIENCES: Q1 REVENUE 80B RUPEES VS 66B (YOY)

 11 Aug 2026 01:24 PM

ZYDUS LIFESCIENCES: Q1 REVENUE 80B RUPEES VS 66B (YOY)

ZYDUS LIFESCIENCES: Q1 EBITDA 19.3B RUPEES VS 20.88B (YOY) || Q1 EBITDA MARGIN 24.07% VS 31.8% (YOY)

 11 Aug 2026 01:24 PM

ZYDUS LIFESCIENCES: Q1 EBITDA 19.3B RUPEES VS 20.88B (YOY) || Q1 EBITDA MARGIN 24.07% VS 31.8% (YOY)

Zydus Life: Receives USFDA Final Approval For Indocyanine Green Injection With 180-Day CGT Exclusivity

 04 Aug 2026 03:10 PM

Zydus Life: Receives USFDA Final Approval For Indocyanine Green Injection With 180-Day CGT Exclusivity

Zydus Lifesciences: Company Gets USFDA EIR for Injectable Facility with VAI Classification.

 01 Aug 2026 03:49 PM

Zydus Lifesciences: Company Gets USFDA EIR for Injectable Facility with VAI Classification.

Zydus Lifesciences: Co. Gets Green Light For Phase III Trial Of Desidustat For Sickle Cell Disease Patients In Partnership With ICMR; Phase II Trial Achieved Main Goals; Desidustat Has Orphan Drug Status From US FDA.

 23 Jul 2026 10:05 AM

Zydus Lifesciences: Co. Gets Green Light For Phase III Trial Of Desidustat For Sickle Cell Disease Patients In Partnership With ICMR; Phase II Trial Achieved Main Goals; Desidustat Has Orphan Drug Status From US FDA.

Zydus Life: Co To Consider Q1 Results On August 11.

 20 Jul 2026 12:54 PM

Zydus Life: Co To Consider Q1 Results On August 11.